City
Epaper

Study shows tumour DNA in blood can predict lung cancer outcome

By IANS | Updated: January 13, 2025 16:35 IST

New Delhi, Jan 13 A team of British scientists has found that a blood test used to detect ...

Open in App

New Delhi, Jan 13 A team of British scientists has found that a blood test used to detect circulating tumour DNA can predict the outcome of lung cancer.

Circulating tumour DNA (ctDNA) is fragments of DNA released into the blood by tumours. It’s known to be important for disease prognosis but can be difficult to measure precisely.

In the study, scientists from the Francis Crick Institute and University College London used a whole-genome sequencing platform called NeXT Personal, which can detect very small amounts -- 1 part per million -- of ctDNA.

They used the platform to test blood plasma samples from 171 people with early-stage lung cancer.

The finding published on Monday in the journal Nature Medicine showed that people with a low level of ctDNA before surgery were less likely to relapse and had improved overall survival rates than people with a high level of ctDNA.

The high sensitivity of the test meant that smaller amounts of ctDNA could be detected, which prevented people with a lower amount of ctDNA from being incorrectly labelled ctDNA negative.

“We’ve shown that the presence or absence of tumour DNA in the blood was strongly predictive of prognosis. ctDNA testing, especially using ultrasensitive platforms, could help clinicians make more informed decisions about treatment and give patients a more accurate idea of how their disease might progress,” said James Black, Postdoctoral Clinical Fellow at the Francis Crick Institute.

Current treatment for early-stage lung cancer includes removing the tumour by surgery and with chemotherapy or immunotherapy. The treatment course depends on the stage of the tumour, which aims to achieve the highest chance of cure.

Meanwhile, the team noted that the test will next be assessed on samples from patients who have undergone surgery with the earliest stages of lung cancer. This will help evaluate if the presence of ctDNA post-operatively in blood can be used to infer future risk of relapse.

This could allow doctors to offer additional therapy after surgery, increasing the chance of curing patients, the scientists said.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

NashikNashik Accident: 12-Year-Old Schoolgirl Killed After Being Run Over by Speeding Dumper While Cycling to School

Other Sports"Created something special": Chennai Bulls head coach Ben Gollings on RPL's transformative impact in India

NationalOutgoing Himachal BJP chief Rajeev Bindal set to retrain post for third term

BusinessTaiwan and UK sign landmark trade pacts to bolster bilateral ties

EntertainmentSita Ramam, Pippa to Hi Nanna: 5 Mrunal Thakur Starrers to Watch Before Son of Sardaar 2

Technology Realted Stories

TechnologyNIT Rourkela-led study shows how dust, water ice influence Martian atmosphere

Technology1st phase of India’s Deep Ocean Mission on track for sea trials in early 2026: Minister

TechnologyAdani Electricity observes National Electrical Safety Week

TechnologyPresident Murmu calls for chemical-free, low-cost treatments for better animal healthcare

TechnologySensex, Nifty end lower after rising for 4 straight sessions